Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has announced its upcoming participation at the 7th Annual Evercore HealthCONx Conference. The presentation is scheduled for Tuesday, December 3 at 2:35 p.m. ET.
Interested parties can access the webcast through the 'Events & Presentations' section on the company's investor relations website at investors.dynavax.com/events-presentations.
Dynavax Technologies has announced a $100 million Accelerated Share Repurchase (ASR) program under an agreement with Goldman Sachs & Co. . This ASR is part of a $200 million share repurchase program authorized by Dynavax's Board of Directors in November 2024. Upon completion, $100 million will remain in the program.
Dynavax will initially receive approximately 6.1 million shares, representing around 80% of the $100 million paid, based on the $13.01 closing stock price on November 8, 2021. The final number of shares repurchased will be determined by the volume-weighted average prices during the ASR term, with final settlement expected in Q1 2025. As of November 5, 2024, Dynavax had about 131.5 million shares outstanding.
Chief Financial Officer Kelly MacDonald stated that the ASR reflects confidence in Dynavax's business and commitment to shareholder value through strategic capital allocation.
Dynavax (DVAX) reported strong Q3 2024 financial results, with HEPLISAV-B achieving record quarterly net product revenue of $79.3 million, up 27% year-over-year. The company's total revenues reached $80.6 million, a 16% increase from Q3 2023. HEPLISAV-B's U.S. market share grew to 44%, with particularly strong performance in retail pharmacy (55%) and IDN segments (56%). The company expects the hepatitis B adult vaccine market to reach over $900 million by 2030, with HEPLISAV-B targeting at least 60% market share. Dynavax reported net income of $17.6 million and maintains a strong cash position of $764 million. The company also announced a $200 million share repurchase program and discontinued its Tdap-1018 development program.
Dynavax Technologies (Nasdaq: DVAX) has announced a new $200 million share repurchase program with no expiration date, expected to be executed within one year. The company's management will determine the timing and amount of repurchases based on business capital needs, stock price, and market conditions. The program can be implemented through various methods including open market purchases and block trades, and can be suspended at any time. CFO Kelly MacDonald emphasized this aligns with their disciplined capital allocation approach, aiming to create shareholder value while maintaining flexibility for HEPLISAV-B development, research pipeline advancement, and portfolio expansion.
Dynavax Technologies (DVAX) has implemented a -duration stockholder rights plan in response to Deep Track Capital's recent accumulation of 13.6% of company stock. The plan grants stockholders one preferred share purchase right per common share as of November 8, 2024. Rights become exercisable if any entity acquires 15% ownership (18% for passive institutional investors), allowing holders to purchase additional shares at $52.00. The plan aims to protect stockholder value and prevent control acquisition without appropriate premium. The Rights Plan will be submitted for stockholder vote at the 2025 Annual Meeting and will expire thereafter unless ratified, in which case it continues until October 28, 2025.
Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on vaccine development, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Interested parties can access the webcast through the company's investor relations website, with a replay available for 30 days. Participants are advised to register and connect 10 minutes before the call.
Dynavax Technologies (Nasdaq: DVAX) reported strong Q2 2024 financial results, highlighting record HEPLISAV-B net product revenue of $70.2 million, a 24% year-over-year increase. The company reaffirmed its full-year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million. Dynavax's total estimated market share in the U.S. increased to approximately 42%, with significant growth in retail pharmacy and IDN segments.
The company initiated dosing in a Phase 1/2 trial for its novel shingles vaccine program, with clinical data expected in 2H 2025. Dynavax also provided updates on its Tdap and plague vaccine programs. Financially, the company reported total revenues of $73.8 million, a 22% year-over-year increase, and net income of $11.4 million or $0.09 per share basic. Cash and marketable securities stood at $735.6 million as of June 30, 2024.
Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on innovative vaccines, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, after U.S. financial markets close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET/1:30 p.m. PT.
Investors can access the live audio webcast through the 'Events & Presentations' page on the company's website. A replay will be available for 30 days following the event. To participate in the call, attendees must register using the provided caller registration link. It is recommended that participants join the conference call or webcast approximately 10 minutes before the scheduled start time.
Dynavax Technologies (Nasdaq: DVAX) has initiated a Phase 1/2 clinical trial of its investigational shingles vaccine, Z-1018. The study will assess the vaccine’s safety, tolerability, and immunogenicity in approximately 440 healthy adults aged 50-69 years in Australia. Z-1018, which uses the CpG 1018 adjuvant, aims to provide improved tolerability and strong CD4+ T-cell responses compared to the market-leading Shingrix® vaccine. The trial will determine the optimal dose and schedule for future studies and validate a Patient Reported Outcome measurement tool for differentiating Z-1018 on tolerability. Top-line results are expected in the second half of 2025.
Dynavax Technologies (Nasdaq: DVAX), a biopharmaceutical company focused on innovative vaccines, will present at two investor conferences in June 2024. The company will participate in the William Blair 44th Annual Growth Stock Conference on June 4 at 1:20 PM CT and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 4:00 PM ET. Webcasts of these presentations will be accessible on the company's website.
FAQ
What is the current stock price of Dynavax Technologies Corporation (DVAX)?
What is the market cap of Dynavax Technologies Corporation (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
